Histamine News and Research RSS Feed - Histamine News and Research

Histamine is a biogenic amine chemical involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.
Current drugs may harbor small-cell lung cancer promise

Current drugs may harbor small-cell lung cancer promise

Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease. [More]
Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada. [More]
TSRI scientists identify set of compounds to treat multiple sclerosis in new way

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers. [More]
Study proposes novel treatment for narcolepsy

Study proposes novel treatment for narcolepsy

Lancet Neurology, a prestigious journal in its domain, publishes in its last issue, an article entitled "Pitolisant versus placebo and modafinil in patients with narcolepsy: a double-blind randomised trial" authored by Y. Dauvilliers and others from the HARMONY I study group which proposes a novel treatment for this orphan disease. It is accompanied by a Commentary entitled "A need for new treatments in narcolepsy". [More]
Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection. [More]
Cleaning product-related asthma goes beyond irritation

Cleaning product-related asthma goes beyond irritation

Research from Belgium indicates that a substantial proportion of those who have occupational asthma related to cleaning agents have specific airway sensitivity to the components of detergents. [More]
Proper precautions may help people with allergies enjoy the beautiful fall weather

Proper precautions may help people with allergies enjoy the beautiful fall weather

As summer comes to a close, kids head back to school and preparation for fall begins, don't' forget to consider fall allergies. An estimated 35 million Americans suffer from allergies, which in the fall begin in late August and peak in September. For those with fall allergies, three triggers typically occur - ragweed, indoor allergens and infections. [More]
Study: H3 receptor antagonist can improve brain edema in adult hypoxic rats

Study: H3 receptor antagonist can improve brain edema in adult hypoxic rats

Thioperamide, a selective histamine H3 receptor antagonist, can increase histamine content in the brain and improve brain edema in adult hypoxic rats. Brain edema is precisely considered as the important pathological change of neonatal hypoxic-ischemic encephalopathy. [More]
Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

Virginia Commonwealth University receives $1.8M grant to study biology of allergic disease

The National Institutes of Health has awarded Virginia Commonwealth University a grant totaling $1.8 million to study the biology of allergic disease - work which may one day point researchers to the development of therapies to fight asthma, allergy and inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and heart disease. [More]
TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

TSRI scientists study 3-D structure of glucagon receptor for treatment of diabetes

The study is reported on July 17, 2013, in an advance online edition of the journal Nature, alongside a British laboratory's structural study of another member of the same class of receptors-known as "class B" G protein-coupled receptors (GPCRs). [More]
Study shows possible biological cause of narcolepsy

Study shows possible biological cause of narcolepsy

In 2000, researchers at the UCLA Center for Sleep Research published findings showing that people suffering from narcolepsy, a disorder characterized by uncontrollable periods of deep sleep, had 90 percent fewer neurons containing the neuropeptide hypocretin in their brains than healthy people. [More]
Researchers find new treatment option for schizophrenia

Researchers find new treatment option for schizophrenia

A research group led by professor Jesper Ekelund showed that by giving a very large dose of famotidine (200 mg daily), sufficient amounts of the drug are able to penetrate the so-called blood-brain barrier to affect the histamine system in the brain. [More]
People with narcolepsy have increased number of neurons that produce histamine

People with narcolepsy have increased number of neurons that produce histamine

A new study provides surprising evidence that people with narcolepsy have an increased number of neurons that produce histamine, suggesting that histamine signaling may be a novel therapeutic target for this potentially disabling sleep disorder. [More]
Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder. [More]
Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Antihistamine drugs work by preventing histamine from attaching to H1 receptors

Itchy eyes, scratchy throat, running nose--it's allergy season! What triggers these allergic reactions, and how do allergy medications work? [More]
New study examines role of mast cells in development of idiopathic pulmonary fibrosis

New study examines role of mast cells in development of idiopathic pulmonary fibrosis

Pulmonary fibrosis is a chronic, deadly disease that affects five million people worldwide. It is irreversible, its cause is poorly understood, and it has a median survival of only about 3 years. [More]
Nine Nobel laureates to present their research at American Chemical Society meeting

Nine Nobel laureates to present their research at American Chemical Society meeting

At least nine Nobel laureates have research that will be presented here this week during the 245th National Meeting & Exposition of the American Chemical Society, the world's largest scientific society. [More]
Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

Tris Pharma gets FDA NDA approval for Karbinal ER Extended-release Oral Suspension

Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up. [More]

Patients taking antihistamines to suppress stomach acid are at greater risk of C. diff infection

Patients receiving antihistamines to suppress stomach acid are at greater risk of infection from Clostridium difficile, or C. diff, a common cause of diarrhea, particularly in health care settings, Mayo Clinic researchers have found. [More]
Study shows why certain drugs that interact with serotonin receptors have harmful effects

Study shows why certain drugs that interact with serotonin receptors have harmful effects

A team including scientists from The Scripps Research Institute (TSRI), the University of North Carolina at Chapel Hill and the Chinese Academy of Sciences has determined and analyzed the high-resolution atomic structures of two kinds of human serotonin receptor. [More]